Project Grant HT94252410240
Award Date
9/30/24
Completion Date
9/29/26
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance...
The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...
The federal Project Grant award of $1,103,084 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding the development of a personalized blood-based diagnostic assay for the early detection of amyotrophic lateral sclerosis (ALS). The prime awardee, Arizona State University's Division Orspa, is leading the research effort. The project will run from November 1, 2024 to October 31, 2026.
As a sub-award under this grant, Georgetown University is...
The Massachusetts Institute of Technology (MIT) has been awarded a $1,589,772 federal Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). The grant, effective September 1, 2024 through August 31, 2027, will fund the development of a novel mHealth balance assessment and rehabilitation system for Neurofibromatosis Type 2 (NF2) using computer vision and artificial intelligence technologies. The project aims to transform healthcare for...
The Defense Health Agency awarded a $1,210,500 Project Grant to Mayo Clinic under the Military Medical Research and Development program (CFDA 12.420) to explore novel biomarkers for amyotrophic lateral sclerosis (ALS) using a multiomics approach. The award, effective April 1, 2025 through March 31, 2028, will support research involving immunoprofiling, extracellular vesicle analysis, and TDP-43 aggregation assays. This project aims to advance the understanding of ALS pathogenesis and identify...
The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....
The University of Massachusetts Medical School was awarded a $1,005,000 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to develop pad inhibitors for the treatment of amyotrophic lateral sclerosis (ALS). The award, which commenced on September 30, 2024, will support research activities through September 29, 2026. The Medical School's Grants and Contracts Administration division, doing business as UMms, will lead the project...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts was awarded a $1,296,751 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on June 1, 2024, will fund a 2-year research project titled "Electrical Impedance Myography via the Myolex mScan as an ALS Biomarker." The goal of the project is to evaluate a novel diagnostic approach using electrical impedance...
The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...